Skip to main content

Advertisement

SpringerLink
Log in

Key emerging issues in progressive supranuclear palsy and corticobasal degeneration

  • Neurological Update
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

It has been approximately 50 years since neurologists were introduced to the entities, “progressive supranuclear palsy” and “corticobasal degeneration”. Since the two seminal publications, there have been significant advancements in our understanding of these two neurodegenerative diseases, particularly the fact that both are associated with tau. Recent advances over the past 3 years that are notable to the field are discussed in this review that covers clinical diagnosis, pathological features, neuroimaging and CSF biomarkers, genetic associations and clinical trials related to progressive supranuclear palsy and corticobasal degeneration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Rebeiz JJ, Kolodny EH, Richardson EP Jr (1968) Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 18:20–33

    Article  CAS  PubMed  Google Scholar 

  2. Steele JC, Richardson JC, Olszewski J (1964) Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy Nuchal Dystonia and Dementia. Arch Neurol 10:333–359

    Article  CAS  PubMed  Google Scholar 

  3. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47:1–9

    Article  CAS  PubMed  Google Scholar 

  4. Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh PN (2009) Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 132:156–171

    Article  PubMed Central  PubMed  Google Scholar 

  5. Respondek G, Roeber S, Kretzschmar H, Troakes C, Al-Sarraj S, Gelpi E, Gaig C, Chiu WZ, van Swieten JC, Oertel WH, Hoglinger GU (2013) Accuracy of the National Institute for Neurological Disorders and Stroke/Society for Progressive Supranuclear Palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy. Mov Disord 28:504–509

    Article  PubMed  Google Scholar 

  6. Respondek G, Stamelou M, Kurz C, Ferguson LW, Rajput A, Chiu WZ, van Swieten JC, Troakes C, Al Sarraj S, Gelpi E, Gaig C, Tolosa E, Oertel WH, Giese A, Roeber S, Arzberger T, Wagenpfeil S, Hoglinger GU (2014) The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord 29:1758–1766

    Article  PubMed  Google Scholar 

  7. Josephs KA, Duffy JR, Strand EA, Machulda MM, Senjem ML, Master AV, Lowe VJ, Jack CR Jr, Whitwell JL (2012) Characterizing a neurodegenerative syndrome: primary progressive apraxia of speech. Brain 135:1522–1536

    Article  PubMed Central  PubMed  Google Scholar 

  8. Josephs KA, Duffy JR, Strand EA, Machulda MM, Senjem ML, Gunter JL, Schwarz CG, Reid RI, Spychalla AJ, Lowe VJ, Jack CR Jr, Whitwell JL (2014) The evolution of primary progressive apraxia of speech. Brain 137:2783–2795

    Article  PubMed  Google Scholar 

  9. Duff K, Gerstenecker A, Litvan I (2013) Functional impairment in progressive supranuclear palsy. Neurology 80:380–384

    Article  PubMed Central  PubMed  Google Scholar 

  10. Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, Boxer AL, Dickson DW, Grossman M, Hallett M, Josephs KA, Kertesz A, Lee SE, Miller BL, Reich SG, Riley DE, Tolosa E, Troster AI, Vidailhet M, Weiner WJ (2013) Criteria for the diagnosis of corticobasal degeneration. Neurology 80:496–503

    Article  PubMed Central  PubMed  Google Scholar 

  11. Alexander SK, Rittman T, Xuereb JH, Bak TH, Hodges JR, Rowe JB (2014) Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. J Neurol Neurosurg Psychiatry 85:925–929

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Ouchi H, Toyoshima Y, Tada M, Oyake M, Aida I, Tomita I, Satoh A, Tsujihata M, Takahashi H, Nishizawa M, Shimohata T (2014) Pathology and sensitivity of current clinical criteria in corticobasal syndrome. Mov Disord 29:238–244

    Article  PubMed  Google Scholar 

  13. Ferrer I, Lopez-Gonzalez I, Carmona M, Arregui L, Dalfo E, Torrejon-Escribano B, Diehl R, Kovacs GG (2014) Glial and neuronal tau pathology in tauopathies: characterization of disease-specific phenotypes and tau pathology progression. J Neuropathol Exp Neurol 73:81–97

    Article  CAS  PubMed  Google Scholar 

  14. Gerson JE, Sengupta U, Lasagna-Reeves CA, Guerrero-Munoz MJ, Troncoso J, Kayed R (2014) Characterization of tau oligomeric seeds in progressive supranuclear palsy. Acta Neuropathol Commun 2:73

    Article  PubMed Central  PubMed  Google Scholar 

  15. Clavaguera F, Akatsu H, Fraser G, Crowther RA, Frank S, Hench J, Probst A, Winkler DT, Reichwald J, Staufenbiel M, Ghetti B, Goedert M, Tolnay M (2013) Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci USA 110:9535–9540

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Whitwell JL, Avula R, Master A, Vemuri P, Senjem ML, Jones DT, Jack CR Jr, Josephs KA (2011) Disrupted thalamocortical connectivity in PSP: a resting-state fMRI, DTI, and VBM study. Parkinsonism Relat Disord 17:599–605

    Article  PubMed Central  PubMed  Google Scholar 

  17. Worker A, Blain C, Jarosz J, Chaudhuri KR, Barker GJ, Williams SC, Brown RG, Leigh PN, Dell’Acqua F, Simmons A (2014) Diffusion tensor imaging of Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy: a tract-based spatial statistics study. PLoS One 9:e112638

    Article  PubMed Central  PubMed  Google Scholar 

  18. Whitwell JL, Schwarz CG, Reid RI, Kantarci K, Jack CR Jr, Josephs KA (2014) Diffusion tensor imaging comparison of progressive supranuclear palsy and corticobasal syndromes. Parkinsonism Relat Disord 20:493–498

    Article  PubMed  Google Scholar 

  19. Gardner RC, Boxer AL, Trujillo A, Mirsky JB, Guo CC, Gennatas ED, Heuer HW, Fine E, Zhou J, Kramer JH, Miller BL, Seeley WW (2013) Intrinsic connectivity network disruption in progressive supranuclear palsy. Ann Neurol 73:603–616

    Article  PubMed Central  PubMed  Google Scholar 

  20. Massey LA, Jager HR, Paviour DC, O’Sullivan SS, Ling H, Williams DR, Kallis C, Holton J, Revesz T, Burn DJ, Yousry T, Lees AJ, Fox NC, Micallef C (2013) The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy. Neurology 80:1856–1861

    Article  PubMed Central  PubMed  Google Scholar 

  21. Whitwell JL, Jack CR Jr, Parisi JE, Gunter JL, Weigand SD, Boeve BF, Ahlskog JE, Petersen RC, Dickson DW, Josephs KA (2013) Midbrain atrophy is not a biomarker of progressive supranuclear palsy pathology. Eur J Neurol 20:1417–1422

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Whitwell JL, Xu J, Mandrekar J, Gunter JL, Jack CR Jr, Josephs KA (2012) Imaging measures predict progression in progressive supranuclear palsy. Mov Disord 27:1801–1804

    Article  PubMed  Google Scholar 

  23. Reginold W, Lang AE, Marras C, Heyn C, Alharbi M, Mikulis DJ (2014) Longitudinal quantitative MRI in multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat Disord 20:222–225

    Article  PubMed  Google Scholar 

  24. Josephs KA, Xia R, Mandrekar J, Gunter JL, Senjem ML, Jack CR Jr, Whitwell JL (2013) Modeling trajectories of regional volume loss in progressive supranuclear palsy. Mov Disord 28:1117–1124

    Article  PubMed  Google Scholar 

  25. Zalewski N, Botha H, Whitwell JL, Lowe V, Dickson DW, Josephs KA (2014) FDG-PET in pathologically confirmed spontaneous 4R-tauopathy variants. J Neurol 261:710–716

    Article  CAS  PubMed  Google Scholar 

  26. Niethammer M, Tang CC, Feigin A, Allen PJ, Heinen L, Hellwig S, Amtage F, Hanspal E, Vonsattel JP, Poston KL, Meyer PT, Leenders KL, Eidelberg D (2014) A disease-specific metabolic brain network associated with corticobasal degeneration. Brain 137:3036–3046

    Article  PubMed  Google Scholar 

  27. Botha H, Whitwell JL, Madhaven A, Senjem ML, Lowe V, Josephs KA (2014) The pimple sign of progressive supranuclear palsy syndrome. Parkinsonism Relat Disord 20:180–185

    Article  PubMed  Google Scholar 

  28. Zwergal A, la Fougere C, Lorenzl S, Rominger A, Xiong G, Deutschenbaur L, Schoberl F, Linn J, Dieterich M, Brandt T, Strupp M, Bartenstein P, Jahn K (2013) Functional disturbance of the locomotor network in progressive supranuclear palsy. Neurology 80:634–641

    Article  PubMed  Google Scholar 

  29. Wagshal D, Sankaranarayanan S, Guss V, Hall T, Berisha F, Lobach I, Karydas A, Voltarelli L, Scherling C, Heuer H, Tartaglia MC, Miller Z, Coppola G, Ahlijanian M, Soares H, Kramer JH, Rabinovici GD, Rosen HJ, Miller BL, Meredith J, Boxer AL (2014) Divergent CSF tau alterations in two common tauopathies: Alzheimer’s disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 86:244–250

    Article  PubMed Central  PubMed  Google Scholar 

  30. Hoglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, van Swieten JC, Heutink P, Wszolek ZK, Uitti RJ, Vandrovcova J, Hurtig HI, Gross RG, Maetzler W, Goldwurm S, Tolosa E, Borroni B, Pastor P, Cantwell LB, Han MR, Dillman A, van der Brug MP, Gibbs JR, Cookson MR, Hernandez DG, Singleton AB, Farrer MJ, Yu CE, Golbe LI, Revesz T, Hardy J, Lees AJ, Devlin B, Hakonarson H, Muller U, Schellenberg GD (2011) Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 43:699–705

    Article  PubMed Central  PubMed  Google Scholar 

  31. Ferrari R, Ryten M, Simone R, Trabzuni D, Nicolaou N, Hondhamuni G, Ramasamy A, Vandrovcova J, Weale ME, Lees AJ, Momeni P, Hardy J, de Silva R (2014) Assessment of common variability and expression quantitative trait loci for genome-wide associations for progressive supranuclear palsy. Neurobiol Aging 35(1514):e1511–e1512

    Google Scholar 

  32. Fekete R, Bainbridge M, Baizabal-Carvallo JF, Rivera A, Miller B, Du P, Kholodovych V, Powell S, Ondo W (2013) Exome sequencing in familial corticobasal degeneration. Parkinsonism Relat Disord 19:1049–1052

    Article  PubMed Central  PubMed  Google Scholar 

  33. Kouri N, Carlomagno Y, Baker M, Liesinger AM, Caselli RJ, Wszolek ZK, Petrucelli L, Boeve BF, Parisi JE, Josephs KA, Uitti RJ, Ross OA, Graff-Radford NR, DeTure MA, Dickson DW, Rademakers R (2014) Novel mutation in MAPT exon 13 (p. N410H) causes corticobasal degeneration. Acta Neuropathol 127:271–282

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Graff-Radford J, Whitwell JL, Dickson DW, Josephs KA (2013) Pallidonigroluysian atrophy associated with p. A152T variant in MAPT. Parkinsonism Relat Disord 19:838–841

    Article  PubMed  Google Scholar 

  35. Tolosa E, Litvan I, Hoglinger GU, Burn D, Lees A, Andres MV, Gomez-Carrillo B, Leon T, Del Ser T (2014) A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord 29:470–478

    Article  CAS  PubMed  Google Scholar 

  36. Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Golbe LI, Williams DR, Corvol JC, Ludolph A, Burn D, Lorenzl S, Litvan I, Roberson ED, Hoglinger GU, Koestler M, Jack CR Jr, Van Deerlin V, Randolph C, Lobach IV, Heuer HW, Gozes I, Parker L, Whitaker S, Hirman J, Stewart AJ, Gold M, Morimoto BH (2014) Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol 13:676–685

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Whitwell JL, Xu J, Mandrekar JN, Gunter JL, Jack CR Jr, Josephs KA (2012) Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: determining sample size for treatment trials. Parkinsonism Relat Disord 18:252–256

    Article  PubMed Central  PubMed  Google Scholar 

  38. Litvan I, Kong M (2014) Rate of decline in progressive supranuclear palsy. Mov Disord 29:463–468

    Article  PubMed  Google Scholar 

  39. Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, Shankle WR, Elizarov A, Kolb HC (2013) Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 34:457–468

    CAS  PubMed  Google Scholar 

  40. Okamura N, Furumoto S, Harada R, Tago T, Yoshikawa T, Fodero-Tavoletti M, Mulligan RS, Villemagne VL, Akatsu H, Yamamoto T, Arai H, Iwata R, Yanai K, Kudo Y (2013) Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med 54:1420–1427

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Behavioural Neurology and Movement Disorders, Mayo Clinic, Rochester, MN, 55905, USA

    Keith A. Josephs

Authors
  1. Keith A. Josephs
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Keith A. Josephs.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Josephs, K.A. Key emerging issues in progressive supranuclear palsy and corticobasal degeneration. J Neurol 262, 783–788 (2015). https://doi.org/10.1007/s00415-015-7682-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-015-7682-y

Keywords

Search

Navigation